Development of a large scale human complement source for use in bacterial immunoassays

Journal of Immunological Methods

Volumn 391, Issue 1-2, 2013, Pages 39-49

  Brookes, Charlotte ^a   Kuisma, Eeva ^a   Alexander, Frances ^a   Allen, Lauren ^a   Tipton, Thomas ^a   Ram, Sanjay ^a   Gorringe, Andrew ^a   Taylor, Stephen ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

Bactericidal; Complement; IgG depletion; Immunoassay; Neisseria

Indexed keywords

COMPLEMENT; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C2; COMPLEMENT COMPONENT C5; COMPLEMENT FACTOR H; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LEPIRUDIN; PROPERDIN; PROTEIN G; SEPHAROSE;

AFFINITY CHROMATOGRAPHY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; HEMOLYSIS; IMMUNITY; IMMUNOASSAY; MENINGOCOCCOSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, BACTERIAL; CHROMATOGRAPHY, AFFINITY; COMPLEMENT C1Q; COMPLEMENT C3; COMPLEMENT C5; COMPLEMENT FACTOR H; COMPLEMENT PATHWAY, ALTERNATIVE; COMPLEMENT SYSTEM PROTEINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEMOLYSIS; HUMANS; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; NEISSERIA MENINGITIDIS; REPRODUCIBILITY OF RESULTS; SERUM BACTERICIDAL ANTIBODY ASSAY;

BACTERIA (MICROORGANISMS); NEISSERIA;

EID: 84876120325     PISSN: 00221759     EISSN: 18727905     Source Type: Journal    
DOI: 10.1016/j.jim.2013.02.007     Document Type: Article

References (56)

1. Aase A., Herstad T.K., Merino S., Brandsdal K.T., Berdal B.P., Aleksandersen E.M., Aaberge I.S. Opsonophagocytic activity and other serological indications of Bordetella pertussis infection in military recruits in Norway. Clin. Vaccine Immunol. 2007, 14:855.
2. Ala'Aldeen D.A., Borriello S.P. The meningococcal transferrin-binding proteins 1 and 2 are both surface exposed and generate bactericidal antibodies capable of killing homologous and heterologous strains. Vaccine 1996, 14:49.
3. Amara U., Rittirsch D., Flierl M., Bruckner U., Klos A., Gebhard F., Lambris J.D., Huber-Lang M. Interaction between the coagulation and complement system. Adv. Exp. Med. Biol. 2008, 632:71.
4. Andrews N., Borrow R., Miller E. Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England. Clin. Diagn. Lab. Immunol. 2003, 10:780.
5. Balmer P., Borrow R. Serologic correlates of protection for evaluating the response to meningococcal vaccines. Expert Rev. Vaccines 2004, 3:77.
6. Beernink P.T., Shaughnessy J., Braga E.M., Liu Q., Rice P.A., Ram S., Granoff D.M. A meningococcal factor H binding protein mutant that eliminates factor H binding enhances protective antibody responses to vaccination. J. Immunol. 2011, 186:3606.
7. Bjorck L., Kronvall G. Purification and some properties of streptococcal protein G, a novel IgG-binding reagent. J. Immunol. 1984, 133:969.
8. Bjorck L., Miorner H., Kuhnemund O., Kronvall G., Sundler R. On the interaction between beta 2-microglobulin and group A streptococci. Scand. J. Immunol. 1984, 20:69.
9. Blackmore T.K., Sadlon T.A., Ward H.M., Lublin D.M., Gordon D.L. Identification of a heparin binding domain in the seventh short consensus repeat of complement factor H. J. Immunol. 1996, 157:5422.
10. Blackmore T.K., Hellwage J., Sadlon T.A., Higgs N., Zipfel P.F., Ward H.M., Gordon D.L. Identification of the second heparin-binding domain in human complement factor H. J. Immunol. 1998, 160:3342.
11. Borrow R., Aaberge I.S., Santos G.F., Eudey T.L., Oster P., Glennie A., Findlow J., Hoiby E.A., Rosenqvist E., Balmer P., Martin D. Interlaboratory standardization of the measurement of serum bactericidal activity by using human complement against meningococcal serogroup b, strain 44/76-SL, before and after vaccination with the Norwegian MenBvac outer membrane vesicle vaccine. Clin. Diagn. Lab. Immunol. 2005, 12:970.
12. Dunkelberger J.R., Song W.C. Complement and its role in innate and adaptive immune responses. Cell Res. 2010, 20:34.
13. Figueroa J.E., Densen P. Infectious diseases associated with complement deficiencies. Clin. Microbiol. Rev. 1991, 4:359.
14. Findlow J., Taylor S., Aase A., Horton R., Heyderman R., Southern J., Andrews N., Barchha R., Harrison E., Lowe A., Boxer E., Heaton C., Balmer P., Kaczmarski E., Oster P., Gorringe A., Borrow R., Miller E. Comparison and correlation of Neisseria meningitidis serogroup B immunologic assay results and human antibody responses following three doses of the Norwegian meningococcal outer membrane vesicle vaccine MenBvac. Infect. Immun. 2006, 74:4557.
15. Findlow J., Holland A., Martin D., Oster P., Balmer P., Borrow R. Inadequacy of colominic acid as an absorbent intended to facilitate use of complement-preserved baby rabbit serum in the Neisseria meningitidis serogroup B serum bactericidal antibody assay. Clin. Vaccine Immunol. 2007, 14:556.
16. Findlow H., Plikaytis B.D., Aase A., Bash M.C., Chadha H., Elie C., Laher G., Martinez J., Herstad T., Newton E., Viviani S., Papaspyridis C., Kulkarni P., Wilding M., Preziosi M.P., Marchetti E., Hassan-King M., La Force F.M., Carlone G., Borrow R. Investigation of different group A immunoassays following one dose of meningococcal group A conjugate vaccine or A/C polysaccharide vaccine in adults. Clin. Vaccine Immunol. 2009, 16:969.
17. Gill C.J., Ram S., Welsch J.A., DeTora L., Anemona A. Correlation between serum bactericidal activity against Neisseria meningitidis serogroups A, C, W-135 and Y measured using human versus rabbit serum as the complement source. Vaccine 2011, 30:29.
18. Giuntini S., Beernink P.T., Reason D.C., Granoff D.M. Monoclonal antibodies to meningococcal factor H binding protein with overlapping epitopes and discordant functional activity. PLoS One 2012, 7:e34272.
19. Giuntini S., Reason D.C., Granoff D.M. Combined roles of human IgG subclass, alternative complement pathway activation, and epitope density in the bactericidal activity of antibodies to meningococcal factor h binding protein. Infect. Immun. 2012, 80:187.
20. Goldschneider I., Gotschlich E.C., Artenstein M.S. Human immunity to the meningococcus. I. The role of humoral antibodies. J. Exp. Med. 1969, 129:1307.
21. Goldschneider I., Gotschlich E.C., Artenstein M.S. Human immunity to the meningococcus. II. Development of natural immunity. J. Exp. Med. 1969, 129:1327.
22. Gorringe A.R., Reddin K.M., Funnell S.G., Johansson L., Rytkonen A., Jonsson A.B. Experimental disease models for the assessment of meningococcal vaccines. Vaccine 2005, 23:2214.
23. Gorringe A.R., Taylor S., Brookes C., Matheson M., Finney M., Kerr M., Hudson M., Findlow J., Borrow R., Andrews N., Kafatos G., Evans C.M., Read R.C. Phase I safety and immunogenicity study of a candidate meningococcal disease vaccine based on Neisseria lactamica outer membrane vesicles. Clin. Vaccine Immunol. 2009, 16:1113.
24. Granoff D.M., Welsch J.A., Ram S. Binding of complement factor H (fH) to Neisseria meningitidis is specific for human fH and inhibits complement activation by rat and rabbit sera. Infect. Immun. 2009, 77:764.
25. Guttormsen H.K., Mascuch S.J., West J.C., Paoletti L.C. A fluorescence-based opsonophagocytosis assay to measure the functional activity of antibody to group B Streptococcus. Hum. Vaccin. 2009, 5:461.
26. Hellerud B.C., Aase A., Herstad T.K., Naess L.M., Kristiansen L.H., Troseid A.M., Harboe M., Lappegard K.T., Brandtzaeg P., Hoiby E.A., Mollnes T.E. Critical roles of complement and antibodies in host defense mechanisms against Neisseria meningitidis as revealed by human complement genetic deficiencies. Infect. Immun. 2010, 78:802.
27. Henckaerts I., Durant N., De Grave D., Schuerman L., Poolman J. Validation of a routine opsonophagocytosis assay to predict invasive pneumococcal disease efficacy of conjugate vaccine in children. Vaccine 2006, 25:2518.
28. Jodar L., Cartwright K., Feavers I.M. Standardisation and validation of serological assays for the evaluation of immune responses to Neisseria meningitidis serogroup A and C vaccines. Biologicals 2000, 28:193.
29. Kaveri S.V., Maddur M.S., Hegde P., Lacroix-Desmazes S., Bayry J. Intravenous immunoglobulins in immunodeficiencies: more than mere replacement therapy. Clin. Exp. Immunol. 2011, 164(Suppl. 2):2.
30. Keyserling H., Papa T., Koranyi K., Ryall R., Bassily E., Bybel M.J., Sullivan K., Gilmet G., Reinhardt A. Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents. Arch. Pediatr. Adolesc. Med. 2005, 159:907.
31. Kojouharova M., Reid K., Gadjeva M. New insights into the molecular mechanisms of classical complement activation. Mol. Immunol. 2010, 47:2154.
32. Kolb W.P., Kolb L.M., Podack E.R. C1q: isolation from human serum in high yield by affinity chromatography and development of a highly sensitive hemolytic assay. J. Immunol. 1979, 122:2103.
33. Kshirsagar N., Mur N., Thatte U., Gogtay N., Viviani S., Preziosi M.P., Elie C., Findlow H., Carlone G., Borrow R., Parulekar V., Plikaytis B., Kulkarni P., Imbault N., LaForce F.M. Safety, immunogenicity, and antibody persistence of a new meningococcal group A conjugate vaccine in healthy Indian adults. Vaccine 2007, 25(Suppl. 1):A101.
34. Lehner P.J., Davies K.A., Walport M.J., Cope A.P., Wurzner R., Orren A., Morgan B.P., Cohen J. Meningococcal septicaemia in a C6-deficient patient and effects of plasma transfusion on lipopolysaccharide release. Lancet 1992, 340:1379.
35. Lewis L.A., Ngampasutadol J., Wallace R., Reid J.E., Vogel U., Ram S. The meningococcal vaccine candidate neisserial surface protein A (NspA) binds to factor H and enhances meningococcal resistance to complement. PLoS Pathog. 2010, 6:e1001027.
36. Lewis L.A., Carter M., Ram S. The relative roles of factor H binding protein, neisserial surface protein A, and lipooligosaccharide sialylation in regulation of the alternative pathway of complement on meningococci. J. Immunol. 2012, 188:5063.
37. Martino A., Magagnoli C., De Conciliis G., D'Ascenzi S., Forster M.J., Allen L., Brookes C., Taylor S., Bai X., Findlow J., Feavers I.M., Rodger A., Bolgiano B. Structural characterisation, stability and antibody recognition of chimeric NHBA-GNA1030: an investigational vaccine component against Neisseria meningitidis. Vaccine 2012, 30:1330.
38. Maslanka S.E., Gheesling L.L., Libutti D.E., Donaldson K.B., Harakeh H.S., Dykes J.K., Arhin F.F., Devi S.J., Frasch C.E., Huang J.C., Kriz-Kuzemenska P., Lemmon R.D., Lorange M., Peeters C.C., Quataert S., Tai J.Y., Carlone G.M. Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group. Clin. Diagn. Lab. Immunol. 1997, 4:156.
39. Mollnes T.E., Brekke O.L., Fung M., Fure H., Christiansen D., Bergseth G., Videm V., Lappegard K.T., Kohl J., Lambris J.D. Essential role of the C5a receptor in E coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation. Blood 2002, 100:1869.
40. Morgan B.P., Marchbank K.J., Longhi M.P., Harris C.L., Gallimore A.M. Complement: central to innate immunity and bridging to adaptive responses. Immunol. Lett. 2005, 97:171.
41. Plested J.S., Granoff D.M. Vaccine-induced opsonophagocytic immunity to Neisseria meningitidis group B. Clin. Vaccine Immunol. 2008, 15:799.
42. Ray T.D., Lewis L.A., Gulati S., Rice P.A., Ram S. Novel blocking human IgG directed against the pentapeptide repeat motifs of Neisseria meningitidis Lip/H.8 and Laz lipoproteins. J. Immunol. 2011, 186:4881.
43. Reller L.B., MacGregor R.R., Beaty H.N. Bactericidal antibody after colonization with Neisseria meningitidis. J. Infect. Dis. 1973, 127:56.
44. Romero-Steiner S., Libutti D., Pais L.B., Dykes J., Anderson P., Whitin J.C., Keyserling H.L., Carlone G.M. Standardization of an opsonophagocytic assay for the measurement of functional antibody activity against Streptococcus pneumoniae using differentiated HL-60 cells. Clin. Diagn. Lab. Immunol. 1997, 4:415.
45. Sahu A., Pangburn M.K. Identification of multiple sites of interaction between heparin and the complement system. Mol. Immunol. 1993, 30:679.
46. Santos G.F., Deck R.R., Donnelly J., Blackwelder W., Granoff D.M. Importance of complement source in measuring meningococcal bactericidal titers. Clin. Diagn. Lab. Immunol. 2001, 8:616.
47. Schneider M.C., Exley R.M., Ram S., Sim R.B., Tang C.M. Interactions between Neisseria meningitidis and the complement system. Trends Microbiol. 2007, 15:233.
48. Sprong T., Moller A.S., Bjerre A., Wedege E., Kierulf P., van der Meer J.W., Brandtzaeg P., van Deuren M., Mollnes T.E. Complement activation and complement-dependent inflammation by Neisseria meningitidis are independent of lipopolysaccharide. Infect. Immun. 2004, 72:3344.
49. Tao M.H., Canfield S.M., Morrison S.L. The differential ability of human IgG1 and IgG4 to activate complement is determined by the COOH-terminal sequence of the CH2 domain. J. Exp. Med. 1991, 173:1025.
50. Trotter C., Borrow R., Andrews N., Miller E. Seroprevalence of meningococcal serogroup C bactericidal antibody in England and Wales in the pre-vaccination era. Vaccine 2003, 21:1094.
51. Trotter C., Findlow J., Balmer P., Holland A., Barchha R., Hamer N., Andrews N., Miller E., Borrow R. Seroprevalence of bactericidal and anti-outer membrane vesicle antibody to Neisseria meningitidis group B in England. Clin. Vaccine Immunol. 2007, 14:863.
52. Trotter C.L., Borrow R., Findlow J., Holland A., Frankland S., Andrews N.J., Miller E. Seroprevalence of antibodies against serogroup C meningococci in England in the postvaccination era. Clin. Vaccine Immunol. 2008, 15:1694.
53. Trotter C.L., Findlow H., Borrow R. Seroprevalence of serum bactericidal antibodies against group W135 and Y meningococci in England in 2009. Clin. Vaccine Immunol. 2012, 19:219.
54. Vidarsson G., van Der Pol W.L., van Den Elsen J.M., Vile H., Jansen M., Duijs J., Morton H.C., Boel E., Daha M.R., Corthesy B., van De Winkel J.G. Activity of human IgG and IgA subclasses in immune defense against Neisseria meningitidis serogroup B. J. Immunol. 2001, 166:6250.
55. World Health Organisation W. Requirements for meningococcal polysaccharide vaccine (requirements for biological substances no. 23). World Health Organ. Tech. Rep. Ser. 1976, 594:72.
56. Zollinger W.D., Mandrell R.E. Importance of complement source in bactericidal activity of human antibody and murine monoclonal antibody to meningococcal group B polysaccharide. Infect. Immun. 1983, 40:257.